The research team, led by Chisom Chimbundum Adim of the Africa Center of Excellence for Public Health and Toxicological Research, together with Aminanyanaba Onari Asimiea and Ugochi Adaku Okengwu, constructed a deterministic compartmental model of the SEIR-SEI type. In this framework, human hosts move through susceptible, exposed, infectious and recovered states, while mosquito vectors pass through susceptible, exposed and infectious stages. This dual structure captures the essential biology of malaria: the parasite must complete incubation in both a human and an Anopheles mosquito before transmission can continue, and the model tracks those coupled populations simultaneously over time.

Biological parameters governing mosquito longevity, biting behaviour, parasite development rates and recovery times were drawn from the published literature. Crucially, the team anchored their model to reality by calibrating transmission intensity against parasite prevalence among under-five children reported for the study area in the 2021 Nigeria Malaria Indicator Survey. All data cleaning and analysis were performed in the R programming environment, and because the study relied on secondary, anonymised information, the Ethics Research Committee of the University of Port Harcourt approved the work without requiring individual patient consent.

The centrepiece of the analysis is the effective reproduction number, a quantity epidemiologists use to gauge whether an outbreak is growing or shrinking. Derived here using the next-generation-matrix method, the reproduction number represents the average number of secondary infections generated by a single infectious individual in a population where some control measures are already in place. When this number exceeds one, each infection sparks more than one new infection and transmission persists; when it falls below one, the epidemic chain gradually breaks apart.

Under current intervention coverage in Rivers State, the model estimated an effective reproduction number of approximately 2.6, well above the elimination threshold. In other words, even with insecticide-treated nets and artemisinin-based combination therapy deployed at existing levels, every childhood malaria infection is still generating more than two subsequent infections on average. The counterfactual scenario is even starker: without any interventions at all, the reproduction number would climb to roughly 8.5, meaning current programmes are already preventing an enormous volume of transmission, just not enough to turn the tide.

To understand which levers matter most, the researchers performed a sensitivity analysis, systematically varying each model parameter and measuring its influence on transmission. The results were instructive. The mosquito biting rate exerted the strongest positive influence, adding about 1.0 to the reproduction number, followed by the transmission probabilities and the vector-to-host ratio, each contributing roughly 0.5. On the protective side, insecticide-treated-net coverage emerged as the single most powerful brake, subtracting about 1.08, with ITN-induced mosquito mortality and natural mosquito mortality contributing further reductions of 0.42 and 0.35 respectively. The message is clear: anything that reduces how often mosquitoes bite humans, or how long mosquitoes live, delivers outsized epidemiological returns.

Scenario analysis then translated these insights into projections for control policy. At present coverage levels, the combined effect of nets and treatment roughly halves the endemic infection prevalence among under-fives, from an estimated 15.8 percent in the absence of control to about 7.5 percent. That is a substantial public health gain, translating into fewer clinical episodes, fewer hospital admissions and fewer deaths among a group whose immature immune systems leave them uniquely vulnerable to severe malaria. Yet the model shows this gain is epidemiologically fragile: with the reproduction number still near 2.6, prevalence rebounds quickly whenever coverage slips.

The pivotal finding concerns what happens when both interventions are scaled up together. The model projects that raising insecticide-treated-net use to at least 80 percent coverage, combined with expanded effective treatment using artemisinin-based combination therapies, drives the reproduction number down to approximately 0.8, below the critical value of one. At that level, each infection generates fewer than one secondary case, and transmission chains begin to collapse, projecting genuine interruption of malaria transmission in the study population. Importantly, neither intervention alone at currently attainable coverage could achieve this; the synergy arises because nets suppress the vector population and biting rate while effective therapy shortens how long infected children remain infectious, attacking the transmission cycle from both directions simultaneously.

These results carry direct implications for malaria control strategy in Rivers State and, by extension, other highly endemic settings in Nigeria. Rather than pursuing nets and drugs as parallel, independently managed programmes, the findings argue for integrated planning in which coverage targets are set jointly and progress is monitored against the reproduction number rather than prevalence alone. The sensitivity analysis offers a practical prioritisation: investments that push net coverage toward and beyond the 80 percent mark, sustain the insecticidal effect that raises mosquito mortality, and ensure that suspected cases receive prompt, effective artemisinin-based therapy will yield the greatest epidemiological payoff. Conversely, complacency about biting-rate drivers, such as unresolved breeding sites and gaps in vector suppression, risks undermining gains made elsewhere.

The study also demonstrates the value of data-driven modelling as a decision-support tool for public health authorities working with limited resources. By calibrating a mechanistic model to national survey data and then testing intervention scenarios computationally, the researchers could compare futures that would be impossible to test experimentally in the field, estimating in advance which combinations of coverage levels are likely to achieve elimination and which will merely blunt the epidemic. As Nigeria pursues its national malaria elimination ambitions, work of this kind suggests that the path forward in Rivers State runs not through any single silver bullet, but through the disciplined, simultaneous scale-up of the two interventions already in the toolbox, guided by models that can tell programme managers precisely how close they are to the tipping point.

Subject of Research: Mathematical modelling of malaria transmission dynamics and intervention strategies in children under five in Rivers State, Nigeria

Article Title: Data-driven modelling of malaria transmission among under-five children to inform targeted control strategies in Rivers State, Nigeria

Article References: Adim, C. C., Asimiea, A. O., & Okengwu, U. A. (2026). Data-driven modelling of malaria transmission among under-five children to inform targeted control strategies in Rivers State, Nigeria. BMC Public Health. https://doi.org/10.1186/s12889-026-29781-0

Image Credits: AI Generated

DOI: 10.1186/s12889-026-29781-0

Keywords: malaria, mathematical modelling, SEIR-SEI model, effective reproduction number, insecticide-treated nets, artemisinin-based combination therapy, under-five children, Rivers State, Nigeria, transmission dynamics, public health, sensitivity analysis

The researchers built their analysis around a mathematical branching-process model, sometimes described as an epidemic tree, that tracks who infected whom through successive generations of a growing outbreak. This transmission genealogy is essential for simulating contact tracing, because tracing only works if the model knows which secondary cases belong to which confirmed positive. Infected individuals in the model pass through a presymptomatic and infectious phase, develop symptoms after an incubation time drawn from a lognormal distribution, and then remain infectious and symptomatic for a period matching the length of their presymptomatic phase, an assumption motivated by the nearly symmetrical infectiousness profile reported for SARS-CoV-2. A fraction of cases remain asymptomatic throughout and can only be caught through contact tracing.

Three strategy parameters govern the model’s mitigation machinery. The test turnaround time measures how long elapses between ordering a test and receiving the result, a delay that includes both waiting for the test itself and waiting for the analysis. Test sensitivity is the probability that a truly infected person tests positive. Tracing efficiency is the fraction of secondary cases successfully found and isolated after a positive result. These parameters are neither fixed nor independent: surges in case numbers can stretch turnaround times, which slows tracing and allows more secondary infections, creating a vicious cycle, while faster tests such as rapid antigen tests generally sacrifice sensitivity compared with slower PCR-based analysis.

To compare strategies, the team computed the effective reproduction number under each combination of parameters, averaging results over hundreds of simulations with offspring drawn from a negative binomial distribution that captures superspreading, with a basic reproduction number of two and parameters otherwise calibrated to SARS-CoV-2. For each choice of tracing efficiency and turnaround time for the slow test, they identified a breaking point: a rapid-test sensitivity below which the accurate test wins and above which the fast test wins. With a tracing efficiency of 80 percent, a rapid test with a one-day turnaround remained preferable even as its sensitivity dropped considerably, whereas when the accurate test’s results took six days to arrive, a rapid test with sensitivity as low as 0.76 still outperformed it.

The broader picture emerged when the researchers varied tracing efficiency across the full range. The breaking-point curves all originate in the lower-right corner of the parameter space, where tests are perfectly accurate but no tracing occurs, and sweep leftward as tracing improves. In other words, the faster test only earns its advantage when contact tracing is there to exploit its speed. For a disease with an infectiousness profile similar to COVID-19, highly accurate tests with turnaround times under six days generally reduce transmission better than less accurate rapid tests for most parameter choices, but highly effective tracing flips the balance in favor of speed.

The shape of the infectiousness profile itself proved decisive. When the team simulated a disease that was twice as infectious during the presymptomatic phase as in the later half of infection, all breaking-point lines shifted left, meaning fast turnaround became more valuable. The logic is intuitive: when most transmission happens early and in people who feel perfectly healthy, identifying infected individuals quickly is paramount, and speed can compensate for a lower probability of detection. Delays, by contrast, waste the narrow window in which intervention does the most good.

The study then relaxed a key simplifying assumption. Real rapid antigen tests do not have a constant sensitivity; their performance tracks the viral load of the infected person. Drawing on a meta-analysis by Brümmer and colleagues that reported an average sensitivity of 76.3 percent for rapid antigen tests, rising above 90 percent in cases with high viral loads, the researchers modeled sensitivity as a weighted function of the infectiousness profile, keeping the average over the course of disease fixed while raising sensitivity on the days when infected people are most contagious. Under this more realistic assumption, the rapid test fared markedly better: for empirically plausible sensitivity values and nearly all levels of contact tracing, the rapid test beat the PCR-style test whenever the slower test’s turnaround exceeded four days. Notably, increasing tracing efficiency from zero to 20 percent substantially boosted the rapid test’s performance, while beyond that threshold both test types benefited similarly, producing nearly vertical breaking-point lines that signal diminishing marginal returns.

Perhaps the most striking result concerns what happens when contact tracing is absent altogether. The researchers proved analytically that in the no-tracing limit, a slow test with perfect sensitivity always reduces infections at least as well as any faster, less accurate alternative, even one with zero turnaround time. The reason lies in the model’s assumption that people isolate while awaiting results. Perfect self-isolation before and during testing does much of the mitigation work, and a false negative releases an infected person early, causing more onward transmission than the delay of an accurate test ever would. Curiously, this means that if everyone adheres strictly to isolation upon symptoms, a strategy of self-isolation without any testing performs at least as well as testing with perfect sensitivity and no delay, although the authors note the practical economic cost of isolating people whose similar symptoms stem from other illnesses.

The analytical framework also clarified how the pieces fit together. The team derived a closed-form expression for the effective reproduction number in which the mitigation policy appears as a subtraction term from the basic reproduction number, and they showed that the contribution of test sensitivity is linear in the no-tracing case. Extending the analysis to contact tracing introduced genuine complexity, because the probability of being traced depends recursively on whether one’s infector tested positive, which depends on whether the infector was traced in turn, and tracing only succeeds if the traced person is still actively infectious. The researchers resolved this with Monte Carlo estimates of the conditioned distributions sampled from their simulations, achieving close agreement between theory and simulation across most of the parameter space, with divergence appearing only near the epidemic threshold where simulated outbreaks die out quickly.

The authors are careful to frame their conclusions conservatively. Several model assumptions, including perfect isolation compliance, no isolation after a false negative, a relatively low basic reproduction number, and a perfectly sensitive slow test, all tilt the comparison in favor of the accurate test, meaning their findings likely underestimate the benefits of rapid testing. The model considers only forward tracing of descendants of confirmed cases, excludes mass screening and two-way tracing, and does not model explicit tracing delays, each of which could shift the balance further. Still, the practical message is clear: when testing infrastructure comes under severe stress and waiting times balloon, switching to rapid, less sensitive tests can be a viable and even preferable strategy for curbing transmission, provided that contact tracing capacity stands ready to convert fast diagnoses into fast isolation of secondary cases.

Subject of Research: Trade-offs between test sensitivity, turnaround time, and contact tracing efficiency in test-trace-isolate epidemic mitigation strategies

Article Title: Are fast test results preferable to high test sensitivity in contact-tracing strategies?

Article References: Boilesen, M. R., Græsbøll, K., & Juul, J. L. (2026). Are fast test results preferable to high test sensitivity in contact-tracing strategies?. PLOS Complex Systems, 3(10), e0000134. https://doi.org/10.1371/journal.pcsy.0000134

Image Credits: AI Generated

DOI: 10.1371/journal.pcsy.0000134

Keywords: epidemiology, contact tracing, rapid antigen tests, test sensitivity, turnaround time, branching process model, SARS-CoV-2, test-trace-isolate, effective reproduction number, viral load, mathematical modeling, public health

The study rests on a simple but powerful epidemiological premise: antibodies of the immunoglobulin G class persist for years after infection or vaccination, so their prevalence in a population acts as a cumulative record of exposure. Because hepatitis A and hepatitis E are both transmitted primarily through the faecal-oral route, their seroprevalence patterns are tightly coupled to sanitation, water quality, hygiene practices and socio-economic conditions. When a community improves its water and sanitation infrastructure, the age at which children first encounter these viruses tends to rise, shifting the burden of susceptibility toward older individuals in whom infection is more likely to cause symptomatic disease. This phenomenon, known as epidemiological transition, is one of the central concerns for vaccination policy in low- and middle-income countries undergoing rapid urban development.

To test whether such a transition was underway in Vellore, the team drew on biobanked serum samples from 600 participants in the 2013 survey and 558 participants in the 2022 survey, all aged between one and forty years. Each sample was tested for IgG antibodies specific to hepatitis A virus and hepatitis E virus. The investigators then stratified seroprevalence estimates by age, gender and residential cluster, allowing them to detect not only overall changes between the two survey years but also geographic heterogeneity within the city. Statistical comparisons of seropositivity between years were carried out using proportion tests or Fisher’s exact tests, depending on the structure of the data.

The hepatitis A results were striking in their consistency. Seroprevalence exceeded 80 percent among children aged one to five years in both surveys and climbed to 100 percent among individuals aged sixteen and above, in 2013 as well as 2022. No statistically significant differences in hepatitis A seroprevalence were observed between the two survey years in any age stratum. In practical terms, nearly every resident of urban Vellore had been infected with hepatitis A virus by early adulthood in both eras, and infection continued to occur early in childhood. The virus, in this setting, remains firmly endemic, and the population’s collective immunity remains high.

Hepatitis E told a different story. IgG seroprevalence against this virus was low among children and adolescents in both surveys and increased progressively with age, a pattern consistent with sporadic rather than sustained childhood transmission. Among adults aged twenty-six to forty years, seroprevalence rose from 18 percent in 2013, with a 95 percent confidence interval of 12 to 27 percent, to 24 percent in 2022, with a 95 percent confidence interval of 16 to 32 percent. Although this increase suggests a possible gradual accumulation of exposure in adulthood, the change did not reach statistical significance, and the authors are careful not to overinterpret it. Across both viruses, no significant gender-based differences in seropositivity were detected.

Cluster-wise analysis added a spatial dimension to these findings. Hepatitis A seroprevalence was uniformly high across all residential clusters sampled in Vellore, reflecting the pervasive nature of early-life exposure to the virus throughout the urban environment. Hepatitis E seroprevalence, by contrast, was both low and heterogeneous across clusters, indicating that exposure to this virus is patchy and likely driven by localised factors such as intermittent contamination of water supplies, sanitation gaps in specific neighbourhoods, or differences in food handling practices. This heterogeneity matters for surveillance design, because a citywide average can easily mask pockets of elevated risk where outbreaks of hepatitis E, which can be particularly dangerous for pregnant women, may originate.

Beyond simple prevalence counts, the study employed more sophisticated quantitative tools to probe hepatitis A transmission dynamics. The researchers applied contact matrix and mixture modelling to the serological data to estimate the effective reproduction number, Re, for hepatitis A in each survey year. Mixture modelling, which treats the antibody distribution in a population as a blend of distributions from susceptible and immune individuals, allows researchers to infer the force of infection even from cross-sectional snapshots. The analysis yielded an Re below 1 in both serosurveys, indicating that secondary transmission of hepatitis A was not sustaining epidemic growth in either era, despite the accumulation of susceptible individuals in older age groups over time. This finding suggests that while the age profile of susceptibility may be shifting slowly, the underlying transmission intensity has not yet crossed the threshold that would fuel outbreaks among older, more vulnerable populations.

The implications for vaccination policy are significant. In many middle-income countries that have improved sanitation, hepatitis A has transitioned from a disease of early childhood, where infection is usually asymptomatic, to one affecting older children and adults, in whom clinical illness and occasional severe outcomes are more common. This shift is the classic argument for universal childhood hepatitis A vaccination: immunising children early both protects them and reduces circulation, indirectly shielding older susceptible individuals. The Vellore data show that this transition, while anticipated, has not yet materialised in measurable form; immunity remains high and acquired early, and the effective reproduction number remains below one. The authors note that their findings should inform age-specific considerations for hepatitis A vaccination policy in urban India as it undergoes transition, implying that the window for deciding on vaccination strategy remains open but should be monitored with continued serosurveillance.

For hepatitis E, the picture is one of limited but persistent and age-dependent exposure. The low seroprevalence among the young means that a large fraction of the population reaches adulthood without prior immunity, and the gradual rise in seropositivity with age reflects cumulative adult exposure. The authors highlight the need for targeted hepatitis E surveillance, particularly because the virus causes substantial morbidity in pregnant women and can trigger large outbreaks when water supplies are compromised. The modest, non-significant rise in adult seroprevalence between 2013 and 2022 is consistent with continued low-level transmission that could accelerate under adverse conditions, making sustained monitoring essential.

Perhaps the clearest message of the study is a reaffirmation of the value of water, sanitation and hygiene interventions. The stability of hepatitis A immunity over the decade, and the continued containment of hepatitis E transmission below epidemic thresholds, support continued investment in WASH infrastructure as the backbone of enteric virus control in urban India. At the same time, the study demonstrates the power of repeated, geographically stratified serosurveys using biobanked samples to detect epidemiological change before it becomes clinically visible. As Indian cities continue to grow and modernise, the balance between endemic early-childhood infection and emerging adult susceptibility will determine whether hepatitis A vaccination becomes a public health priority, and whether hepatitis E remains a smouldering, localised threat or flares into wider outbreaks. The Vellore data provide a rigorous baseline against which that future can be measured.

Subject of Research: Decadal changes in IgG seroprevalence of hepatitis A and E virus in urban Vellore, India

Article Title: Decadal changes in IgG seroprevalence of hepatitis A and E virus in Urban Vellore, India: Persistent Endemicity or Epidemiological Shift?

Article References: Decadal changes in IgG seroprevalence of hepatitis A and E virus in Urban Vellore, India: Persistent Endemicity or Epidemiological Shift?. (n.d.). https://doi.org/10.1186/s12879-026-14413-0

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14413-0

Keywords: Hepatitis A, Hepatitis E, IgG seroprevalence, serosurvey, enteric infections, WASH, epidemiological transition, urban India, effective reproduction number, vaccination policy, Decadal, changes